Evidence map›Paper›PMID 38748299›Full record

ArticleCancer immunology, immunotherapy : CII2024

GGT5: a potential immunotherapy response inhibitor in gastric cancer by modulating GSH metabolism and sustaining memory CD8+ T cell infiltration.

Wenjing Zhao, Ziwei Liang, Yongshi Yao, Yang Ge, Guangyu An, Ling Duan, Jiannan Yao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Predictors of immunotherapy response in gastric cancer: the role of the tumor microenvironment and integrative predictive models.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wenjing Zhao *Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Ziwei Liang *Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Yongshi YaoBeijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Yang GeBeijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Guangyu AnBeijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Ling DuanBeijing Tiantan Hospital, Capital Medical University, Beijing, China.
Jiannan YaoBeijing Chaoyang Hospital, Capital Medical University, Beijing, China. yaojiannan@mail.ccmu.edu.cn.ORCID http://orcid.org/0000-0002-4982-4460

Funding

Beijing Hospitals Authority Youth Programme QML20210307Beijing Municipal Science and Technology Commission NO. Z221100007422109Interdisciplinary Clinical Research Innovation Team Project CYDXK202206National Natural Science Foundation of China No. 82003057
6 · The paper itself

Abstract

purposeThe variable responses to immunotherapy observed in gastric cancer (GC) patients can be attributed to the intricate nature of the tumor microenvironment. Glutathione (GSH) metabolism significantly influences the initiation and progression of gastric cancer. Consequently, targeting GSH metabolism holds promise for improving the effectiveness of Immune checkpoints inhibitors (ICIs).

methodsWe investigated 16 genes related to GSH metabolism, sourced from the MSigDB database, using pan-cancer datasets from TCGA. The most representative prognosis-related gene was identified for further analysis. ScRNA-sequencing analysis was used to explore the tumor heterogeneity of GC, and the results were confirmed by  Multiplex immunohistochemistry (mIHC).

resultsThrough DEGs, LASSO, univariate and multivariate Cox regression analyses, and survival analysis, we identified GGT5 as the hub gene in GSH metabolism with the potential to promote GC. Combining CIBERSORT, ssGSEA, and scRNA analysis, we constructed the immune architecture of GC. The subpopulations of T cells were isolated, revealing a strong association between GGT5 and memory CD8+ T cells. Furthermore, specimens from 10 GC patients receiving immunotherapy were collected. mIHC was used to assess the expression levels of GGT5 and memory CD8+ T cell markers. Our results established a positive correlation between GGT5 expression, the enrichment of memory CD8+ T cells, and a suboptimal response to immunotherapy.

conclusionsOur study identifies GGT5, a hub gene in GSH metabolism, as a potential therapeutic target for inhibiting the response to immunotherapy in GC patients. These findings offer new insights into strategies for optimizing immunotherapy of GC.

Indexed as

CD8-Positive T-Lymphocytesgamma-GlutamyltransferaseGlutathioneImmunotherapyStomach NeoplasmsTumor MicroenvironmentBiomarkers, TumorFemaleHumansImmune Checkpoint InhibitorsLymphocytes, Tumor-InfiltratingMalePrognosisBiomarkers, Tumorgamma-GlutamyltransferaseGGT5 protein, humanGlutathioneImmune Checkpoint InhibitorsGastric cancerGGT5GSHImmune checkpoints inhibitorsImmunotherapyMemory CD8+ T cells

Identifiers

PMID38748299
PMCPMC11096297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.